{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T07:36:37Z","timestamp":1790235397718,"version":"4.1.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,10,28]],"date-time":"2022-10-28T00:00:00Z","timestamp":1666915200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,10,28]],"date-time":"2022-10-28T00:00:00Z","timestamp":1666915200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019650","name":"Vir Biotechnology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019650","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2023,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Sotrovimab (VIR-7831), a human IgG1\u03ba monoclonal antibody (mAb), binds to a conserved epitope on the SARS-CoV-2 spike protein receptor binding domain (RBD). The Fc region of VIR-7831 contains an LS modification to promote neonatal Fc receptor (FcRn)\u2013mediated recycling and extend its serum half-life. Here, we aimed to evaluate the impact of the LS modification on tissue biodistribution, by comparing VIR-7831 to its non-LS-modified equivalent, VIR-7831-WT, in cynomolgus monkeys.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p><jats:sup>89<\/jats:sup>Zr-based PET\/CT imaging of VIR-7831 and VIR-7831-WT was performed up to 14\u00a0days post injection. All major organs were analyzed for absolute concentration as well as tissue:blood ratios, with the focus on the respiratory tract, and a physiologically based pharmacokinetics (PBPK) model was used to evaluate the tissue biodistribution kinetics. Radiomics features were also extracted from the PET images and SUV values.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>SUV<jats:sub>mean<\/jats:sub> uptake in the pulmonary bronchi for <jats:sup>89<\/jats:sup>Zr-VIR-7831 was statistically higher than for <jats:sup>89<\/jats:sup>Zr-VIR-7831-WT at days 6 (3.43\u2009\u00b1\u20090.55 and 2.59\u2009\u00b1\u20090.38, respectively) and 10 (2.66\u2009\u00b1\u20090.32 and 2.15\u2009\u00b1\u20090.18, respectively), while the reverse was observed in the liver at days 6 (5.14\u2009\u00b1\u20090.80 and 8.63\u2009\u00b1\u20090.89, respectively), 10 (4.52\u2009\u00b1\u20090.59 and 7.73\u2009\u00b1\u20090.66, respectively), and 14 (4.95\u2009\u00b1\u20090.65 and 7.94\u2009\u00b1\u20090.54, respectively). Though the calculated terminal half-life was 21.3\u2009\u00b1\u20093.0\u00a0days for VIR-7831 and 16.5\u2009\u00b1\u20091.1\u00a0days for VIR-7831-WT, no consistent differences were observed in the tissue:blood ratios between the antibodies except in the liver. While the lung:blood SUV<jats:sub>mean<\/jats:sub> uptake ratio for both mAbs was 0.25 on day 3, the PBPK model predicted the total lung tissue and the interstitial space to serum ratio to be 0.31 and 0.55, respectively. Radiomics analysis showed VIR-7831 had mean-centralized PET SUV distribution in the lung and liver, indicating more uniform uptake than VIR-7831-WT.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The half-life extended VIR-7831 remained in circulation longer than VIR-7831-WT, consistent with enhanced FcRn binding, while the tissue:blood concentration ratios in most tissues for both drugs remained statistically indistinguishable throughout the course of the experiment. In the bronchiolar region, a higher concentration of <jats:sup>89<\/jats:sup>Zr-VIR-7831 was detected. The data also allow unparalleled insight into tissue distribution and elimination kinetics of mAbs that can guide future biologic drug discovery efforts, while the residualizing nature of the <jats:sup>89<\/jats:sup>Zr label sheds light on the sites of antibody catabolism.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00259-022-06012-3","type":"journal-article","created":{"date-parts":[[2022,10,28]],"date-time":"2022-10-28T05:03:23Z","timestamp":1666933403000},"page":"667-678","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["In vivo biodistribution and pharmacokinetics of sotrovimab, a SARS-CoV-2 monoclonal antibody, in healthy cynomolgus\u00a0monkeys"],"prefix":"10.1007","volume":"50","author":[{"given":"Tolulope A.","family":"Aweda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shih-Hsun","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen C.","family":"Lenhard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armin","family":"Sepp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tinamarie","family":"Skedzielewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih-Yang","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shelly","family":"Marshall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Haag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Kehler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prabhas","family":"Jagdale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Peter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Schmid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Gehman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minh","family":"Doan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew P.","family":"Mayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Gorycki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Fanget","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Colas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenda","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Curtis C.","family":"Maier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6600-2146","authenticated-orcid":false,"given":"Hasan","family":"Alsaid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,28]]},"reference":[{"key":"6012_CR1","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s40259-021-00471-0","volume":"35","author":"S Ko","year":"2021","unstructured":"Ko S, Jo M, Jung ST. Recent achievements and challenges in prolonging the serum half-lives of therapeutic IgG antibodies through Fc engineering. BioDrugs. 2021;35:147\u201357. https:\/\/doi.org\/10.1007\/s40259-021-00471-0.","journal-title":"BioDrugs."},{"issue":"5","key":"6012_CR2","doi-asserted-by":"publisher","first-page":"422","DOI":"10.4161\/mabs.3.5.16983","volume":"3","author":"TT Kuo","year":"2011","unstructured":"Kuo TT, Aveson VG. Neonatal Fc receptor and IgG-based therapeutics. mAbs. 2011;3(5):422\u201330. https:\/\/doi.org\/10.4161\/mabs.3.5.16983.","journal-title":"mAbs."},{"key":"6012_CR3","doi-asserted-by":"publisher","first-page":"3528","DOI":"10.4049\/jimmunol.170.7.3528","volume":"170","author":"DC Roopenian","year":"2003","unstructured":"Roopenian DC, Christianson GJ, Sproule TJ, Brown AC, Akilesh S, Jung N, et al. The MHC class I-like IgG receptor controls perinatal IgG transport IgG homeostasis and fate of IgG-Fc-coupled drugs. J Immunol. 2003;170:3528\u201333. https:\/\/doi.org\/10.4049\/jimmunol.170.7.3528.","journal-title":"J Immunol."},{"key":"6012_CR4","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1111\/bcpt.12761","volume":"121","author":"IP Nnane","year":"2017","unstructured":"Nnane IP, Han C, Jiao Q, Tam SH, Davis HM, Xu Z. Modification of the Fc region of a human anti-oncostatin M monoclonal antibody for higher affinity to FcRn receptor and extension of half-life in cynomolgus monkeys. Basic Clin Pharmacol Toxicol. 2017;121:13\u201321. https:\/\/doi.org\/10.1111\/bcpt.12761.","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"6012_CR5","doi-asserted-by":"publisher","first-page":"4282","DOI":"10.1074\/jbc.M114.603712","volume":"290","author":"MJ Borrok","year":"2015","unstructured":"Borrok MJ, Wu Y, Beyaz N, Yu XQ, Oganesyan V, Dall\u02bcAcqua WF, et al. pH-dependent binding engineering reveals an FcRn affinity threshold that governs IgG recycling. J Biol Chem. 2015;290:4282\u201390. https:\/\/doi.org\/10.1074\/jbc.M114.603712.","journal-title":"J Biol Chem"},{"key":"6012_CR6","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1080\/19420862.2019.1633883","volume":"11","author":"BC Mackness","year":"2019","unstructured":"Mackness BC, Jaworski JA, Boudanova E, Park A, Valente D, Mauriac C, et al. Antibody Fc engineering for enhanced neonatal Fc receptor binding and prolonged circulation half-life. mAbs. 2019;11:1276\u201388. https:\/\/doi.org\/10.1080\/19420862.2019.1633883.","journal-title":"mAbs."},{"key":"6012_CR7","doi-asserted-by":"publisher","first-page":"23514","DOI":"10.1074\/jbc.M604292200","volume":"281","author":"WF Dall\u02bcAcqua","year":"2006","unstructured":"Dall\u02bcAcqua WF, Kiener PA, Wu H. Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn). J Biol Chem. 2006;281:23514\u201324. https:\/\/doi.org\/10.1074\/jbc.M604292200.","journal-title":"J Biol Chem"},{"key":"6012_CR8","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/nbt.1601","volume":"28","author":"J Zalevsky","year":"2010","unstructured":"Zalevsky J, Chamberlain AK, Horton HM, Karki S, Leung IW, Sproule TJ, et al. Enhanced antibody half-life improves in vivo activity. Nat Biotechnol. 2010;28:157\u20139. https:\/\/doi.org\/10.1038\/nbt.1601.","journal-title":"Nat Biotechnol"},{"key":"6012_CR9","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1101\/2021.03.09.434607","volume":"35","author":"AL Cathcart","year":"2021","unstructured":"Cathcart AL, Havenar-Daughton C, Lempp FA, Ma D, Schmid MA, Agostini ML, et al. The dual function monoclonal antibodies VIR-7831 and VIR-7832 demonstrate potent in vitro and in vivo activity against SARS-CoV-2. bioRxiv. 2021;35:1123. https:\/\/doi.org\/10.1101\/2021.03.09.434607.","journal-title":"bioRxiv"},{"key":"6012_CR10","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1056\/NEJMoa2107934","volume":"385","author":"A Gupta","year":"2021","unstructured":"Gupta A, Gonzalez-Rojas Y, Juarez E, Crespo Casal M, Moya J, Falci DR, et al. Early treatment for COVID-19 with SARS-CoV-2 neutralizing antibody sotrovimab. N Engl J Med. 2021;385:1941\u201350. https:\/\/doi.org\/10.1056\/NEJMoa2107934.","journal-title":"N Engl J Med"},{"key":"6012_CR11","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1038\/nature13612","volume":"514","author":"SY Ko","year":"2014","unstructured":"Ko SY, Pegu A, Rudicell RS, Yang ZY, Joyce MG, Chen X, et al. Enhanced neonatal Fc receptor function improves protection against primate SHIV infection. Nature. 2014;514:642\u20135. https:\/\/doi.org\/10.1038\/nature13612.","journal-title":"Nature"},{"key":"6012_CR12","doi-asserted-by":"publisher","first-page":"e0176075","DOI":"10.1371\/journal.pone.0176075","volume":"12","author":"H Alsaid","year":"2017","unstructured":"Alsaid H, Skedzielewski T, Rambo MV, Hunsinger K, Hoang B, Fieles W, et al. Non invasive imaging assessment of the biodistribution of GSK2849330, an ADCC and CDC optimized anti HER3 mAb, and its role in tumor macrophage recruitment in human tumor-bearing mice. PLoS ONE. 2017;12:e0176075. https:\/\/doi.org\/10.1371\/journal.pone.0176075.","journal-title":"PLoS ONE"},{"key":"6012_CR13","doi-asserted-by":"publisher","unstructured":"Sepp A, Bergstr\u00f6m M, Davies M. Cross-species\/cross-modality physiologically based pharmacokinetics for biologics: 89Zr-labelled albumin-binding domain antibody GSK3128349 in humans. mAbs. 2020;12(1). https:\/\/doi.org\/10.1080\/19420862.2020.1832861","DOI":"10.1080\/19420862.2020.1832861"},{"issue":"4","key":"6012_CR14","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1016\/j.ijrobp.2017.12.268","volume":"102","author":"GJR Cook","year":"2018","unstructured":"Cook GJR, Azad G, Owczarczyk K, Siddique M, Goh V. Challenges and promises of PET radiomics. Int J Radiat Oncol Biol Phys. 2018;102(4):1083\u20139.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"6012_CR15","first-page":"2238","volume":"38","author":"T Lambrou","year":"2011","unstructured":"Lambrou T, Groves AM, Erlandsson K, Screaton N, Endozo R, Win T, et al. The importance of correction for tissue fraction effects in lung PET: preliminary findings. 2011;38:2238\u201346.","journal-title":"The importance of correction for tissue fraction effects in lung PET: preliminary findings"},{"key":"6012_CR16","first-page":"687","volume":"54","author":"TR Hobbs","year":"2015","unstructured":"Hobbs TR, Blue SW, Park BS, Greisel JJ, Conn PM, Pau FK. Measurement of blood volume in adult rhesus macaques (Macaca mulatta). J Am Assoc Lab Anim Sci: JAALAS. 2015;54:687\u201393.","journal-title":"J Am Assoc Lab Anim Sci: JAALAS"},{"key":"6012_CR17","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1007\/s10928-019-09640-9","volume":"46","author":"A Sepp","year":"2019","unstructured":"Sepp A, Meno-Tetang G, Weber A, Sanderson A, Schon O, Berges A. Computer-assembled cross-species\/cross-modalities two-pore physiologically based pharmacokinetic model for biologics in mice and rats. J Pharmacokinet Pharmacodyn. 2019;46:339\u201359. https:\/\/doi.org\/10.1007\/s10928-019-09640-9.","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"6012_CR18","doi-asserted-by":"publisher","first-page":"e104","DOI":"10.1158\/0008-5472.Can-17-0339","volume":"77","author":"JJM van Griethuysen","year":"2017","unstructured":"van Griethuysen JJM, Fedorov A, Parmar C, Hosny A, Aucoin N, Narayan V, et al. Computational radiomics system to decode the radiographic phenotype. Can Res. 2017;77:e104\u20137. https:\/\/doi.org\/10.1158\/0008-5472.Can-17-0339.","journal-title":"Can Res"},{"key":"6012_CR19","unstructured":"scikit-fmm 0.0.9 documentation. https:\/\/pythonhosted.org\/scikit-fmm\/. Accessed 05 Jul 2022."},{"key":"6012_CR20","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1080\/19420862.2018.1462429","volume":"5","author":"A Betts","year":"2018","unstructured":"Betts A, Keunecke A, van Steeg TJ, van der Graaf PH, Avery LB, Jones H, et al. Linear pharmacokinetic parameters for monoclonal antibodies are similar within a species and across different pharmacological targets: a comparison between human, cynomolgus monkey and hFcRn Tg32 transgenic mouse using a population-modeling approach. mAbs. 2018;5:751\u2013164. https:\/\/doi.org\/10.1080\/19420862.2018.1462429.","journal-title":"mAbs"},{"key":"6012_CR21","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1038\/s42003-022-03787-x","volume":"5","author":"TT Gjolberg","year":"2022","unstructured":"Gjolberg TT, Frick R, Mester S, Foss S, Grevys A, Hoydahl LS, et al. Biophysical differences in IgG1 Fc-based therapeutics relate to their cellular handling, interaction with FcRn and plasma half-life. Commun Biol. 2022;5:832. https:\/\/doi.org\/10.1038\/s42003-022-03787-x.","journal-title":"Commun Biol"},{"key":"6012_CR22","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1208\/s12248-016-9911-4","volume":"18","author":"CM Ng","year":"2016","unstructured":"Ng CM, Fielder PJ, Jin J, Deng R. Mechanism-based competitive binding model to investigate the effect of neonatal Fc receptor binding affinity on the pharmacokinetic of humanized anti-VEGF monoclonal IgG1 antibody in cynomolgus monkey. AAPS J. 2016;18:948\u201359. https:\/\/doi.org\/10.1208\/s12248-016-9911-4.","journal-title":"AAPS J"},{"key":"6012_CR23","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1124\/dmd.112.045864","volume":"40","author":"A Datta-Mannan","year":"2012","unstructured":"Datta-Mannan A, Chow CK, Dickinson C, Driver D, Lu J, Witcher DR, et al. FcRn affinity-pharmacokinetic relationship of five human IgG4 antibodies engineered for improved in vitro FcRn binding properties in cynomolgus monkeys. Drug Metab Dispos. 2012;40:1545\u201355. https:\/\/doi.org\/10.1124\/dmd.112.045864.","journal-title":"Drug Metab Dispos"},{"key":"6012_CR24","doi-asserted-by":"publisher","first-page":"2853","DOI":"10.1016\/j.xphs.2017.03.033","volume":"106","author":"SB Jadhav","year":"2017","unstructured":"Jadhav SB, Khaowroongrueng V, Fueth M, Otteneder MB, Richter W, Derendorf H. Tissue distribution of a therapeutic monoclonal antibody determined by large pore microdialysis. J Pharm Sci. 2017;106:2853\u20139. https:\/\/doi.org\/10.1016\/j.xphs.2017.03.033.","journal-title":"J Pharm Sci"},{"key":"6012_CR25","first-page":"3969","volume":"46","author":"DG Covell","year":"1986","unstructured":"Covell DG, Barbet J, Holton OD, Black CD, Parker RJ, Weinstein JN. Pharmacokinetics of monoclonal immunoglobulin G1, F(ab\u02b9)2, and Fab\u02b9 in mice. Can Res. 1986;46:3969\u201378.","journal-title":"Can Res"},{"key":"6012_CR26","doi-asserted-by":"publisher","first-page":"7311","DOI":"10.1113\/jp274819","volume":"595","author":"MJ Eigenmann","year":"2017","unstructured":"Eigenmann MJ, Karlsen TV, Krippendorff BF, Tenstad O, Fronton L, Otteneder MB, et al. Interstitial IgG antibody pharmacokinetics assessed by combined in vivo- and physiologically-based pharmacokinetic modelling approaches. J Physiol. 2017;595:7311\u201330. https:\/\/doi.org\/10.1113\/jp274819.","journal-title":"J Physiol"},{"key":"6012_CR27","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/j.nucmedbio.2010.12.011","volume":"38","author":"DS Abou","year":"2011","unstructured":"Abou DS, Ku T, Smith-Jones PM. In vivo biodistribution and accumulation of 89Zr in mice. Nucl Med Biol. 2011;38:675\u201381. https:\/\/doi.org\/10.1016\/j.nucmedbio.2010.12.011.","journal-title":"Nucl Med Biol"},{"key":"6012_CR28","doi-asserted-by":"crossref","unstructured":"Costa A, Andrade F. 4.4 - Tissue-based in vitro and ex\u00a0vivo\u00a0models for pulmonary permeability studies. In: Sarmento B, editor. Concepts and models for drug permeability studies: Woodhead Publishing; 2016. 255\u201372.","DOI":"10.1016\/B978-0-08-100094-6.00015-8"},{"key":"6012_CR29","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1208\/s12248-009-9157-5","volume":"12","author":"M Tabrizi","year":"2010","unstructured":"Tabrizi M, Bornstein GG, Suria H. Biodistribution mechanisms of therapeutic monoclonal antibodies in health and disease. AAPS J. 2010;12:33\u201343. https:\/\/doi.org\/10.1208\/s12248-009-9157-5.","journal-title":"AAPS J"},{"key":"6012_CR30","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.xphs.2020.05.025","volume":"110","author":"HP Chang","year":"2021","unstructured":"Chang HP, Kim SJ, Shah DK. Whole-body pharmacokinetics of antibody in mice determined using enzyme-linked immunosorbent assay and derivation of tissue interstitial concentrations. J Pharm Sci. 2021;110:446\u201357. https:\/\/doi.org\/10.1016\/j.xphs.2020.05.025.","journal-title":"J Pharm Sci"},{"key":"6012_CR31","doi-asserted-by":"publisher","first-page":"3319","DOI":"10.21037\/jtd.2017.08.17","volume":"9","author":"M Mascalchi","year":"2017","unstructured":"Mascalchi M, Camiciottoli G, Diciotti S. Lung densitometry: why, how and when. J Thorac Dis. 2017;9:3319\u201345.","journal-title":"J Thorac Dis"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-022-06012-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-022-06012-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-022-06012-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,19]],"date-time":"2023-01-19T06:04:24Z","timestamp":1674108264000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-022-06012-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,28]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["6012"],"URL":"https:\/\/doi.org\/10.1007\/s00259-022-06012-3","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,28]]},"assertion":[{"value":"6 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the GSK Policy on the Care, Welfare, and Treatment of Laboratory Animals and was reviewed by the Institutional Animal Care and Use Committee at GSK.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Tolulope A. Aweda, Shih-Hsun Cheng, Stephen C. Lenhard, Tinamarie Skedzielewski, Chih-Yang Hsu, Shelly Marshall, Heather Haag, Jonathan Kehler, Prabhas Jagdale, Andrew Gehman, Minh Doan, Andrew P. Mayer, Peter Gorycki, Curtis C. Maier, and Hasan Alsaid are employees of GSK. Armin Sepp is a former employee of GSK. Alessia Peter, Michael A. Schmid, Marie Fanget, and Brenda Smith are employees of Vir Biotechnology, Inc. Christophe Colas is a former employee of Vir Biotechnology, Inc.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}